Alebund Pharmaceuticals, a biopharmaceutical firm that engages in the development of innovative therapies to treat renal diseases, has notched 200 million yuan ($29.3 million) in a pre-Series C round.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
